Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.

Jakimovski D, Zivadinov R, Ramanthan M, Hagemeier J, Weinstock-Guttman B, Tomic D, Kropshofer H, Fuchs TA, Barro C, Leppert D, Yaldizli Ö, Kuhle J, Benedict RH.

Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428. [Epub ahead of print]

PMID:
31610732
2.

Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis.

Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW, Scher AI, Kuhle J, Ascherio A.

JAMA Neurol. 2019 Sep 13. doi: 10.1001/jamaneurol.2019.3238. [Epub ahead of print]

PMID:
31515562
3.

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.

Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, Leppert D, Matsushita T, Hayashi F, Yamasaki R, Kuhle J, Kira JI.

Neurology. 2019 Sep 24;93(13):e1299-e1311. doi: 10.1212/WNL.0000000000008160. Epub 2019 Aug 30.

PMID:
31471502
4.

Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.

Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Ann Clin Transl Neurol. 2019 Sep;6(9):1757-1770. doi: 10.1002/acn3.50872. Epub 2019 Aug 22.

5.

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.

Cantó E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, Tomic D, Santaniello A, Häring DA, Hollenbach J, Henry RG, Cree BAC, Kappos L, Leppert D, Hauser SL, Benkert P, Oksenberg JR, Kuhle J.

JAMA Neurol. 2019 Aug 12. doi: 10.1001/jamaneurol.2019.2137. [Epub ahead of print]

PMID:
31403661
6.

Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes.

Wong YYM, Bruijstens AL, Barro C, Michalak Z, Melief MJ, Wierenga AF, van Pelt ED, Neuteboom RF, Kuhle J, Hintzen RQ.

Neurology. 2019 Sep 3;93(10):e968-e974. doi: 10.1212/WNL.0000000000008057. Epub 2019 Aug 5.

PMID:
31383792
7.

Serum neurofilament light chain as a prognostic marker in postanoxic encephalopathy.

Disanto G, Prosperetti C, Gobbi C, Barro C, Michalak Z, Cassina T, Kuhle J, Casso G, Agazzi P.

Epilepsy Behav. 2019 Jul 30:106432. doi: 10.1016/j.yebeh.2019.07.033. [Epub ahead of print]

PMID:
31375414
8.

Transient liver injury and severe neonatal cholestasis in infant with glucose-6-phosphate dehydrogenase deficiency due to a new mutation.

Ben Fredj D, Barro C, Joly P, Thomassin N, Collardeau-Frachon S, Plantaz D, Adjaoud D.

Arch Pediatr. 2019 Sep;26(6):370-373. doi: 10.1016/j.arcped.2019.05.005. Epub 2019 Jul 2.

PMID:
31278024
9.

Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.

Wilke C, Pujol-Calderón F, Barro C, Stransky E, Blennow K, Michalak Z, Deuschle C, Jeromin A, Zetterberg H, Schüle R, Höglund K, Kuhle J, Synofzik M.

Clin Chem Lab Med. 2019 Sep 25;57(10):1556-1564. doi: 10.1515/cclm-2019-0015.

PMID:
31251725
10.

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.

Sormani MP, Haering DA, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J.

Ann Clin Transl Neurol. 2019 May 28;6(6):1081-1089. doi: 10.1002/acn3.795. eCollection 2019 Jun.

11.

Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study.

Cuello JP, Martínez Ginés ML, Kuhle J, García Domínguez JM, Lozano Ros A, Romero Delgado F, Higueras Y, Meldaña Rivera A, Goicochea Briceño H, García-Tizon Larroca S, De León-Luis J, Michalak Z, Barro C, Álvarez Lafuente R, Medina Heras S, Fernández Velasco JI, Tejeda-Velarde A, Domínguez-Mozo MI, Muriel A, de Andrés C, Villar LM.

Eur J Neurol. 2019 Sep;26(9):1200-1204. doi: 10.1111/ene.13965. Epub 2019 May 9.

PMID:
30977955
12.

Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy.

van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, Michalak Z, Barro C, van Schaik IN, Kuhle J, Eftimov F.

J Peripher Nerv Syst. 2019 Jun;24(2):187-194. doi: 10.1111/jns.12319. Epub 2019 Apr 29.

PMID:
30973667
13.

Xq22.3q23 microdeletion harboring TMEM164 and AMMECR1 genes: Two case reports confirming a recognizable phenotype with short stature, midface hypoplasia, intellectual delay, and elliptocytosis.

Poreau B, Ramond F, Harbuz R, Satre V, Barro C, Vettier C, Adouard V, Thevenon J, Jouk PS, Coutton C, Touraine R, Dieterich K.

Am J Med Genet A. 2019 Apr;179(4):650-654. doi: 10.1002/ajmg.a.61057. Epub 2019 Feb 8.

PMID:
30737907
14.

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L.

Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.

15.

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.

Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M; Dominantly Inherited Alzheimer Network.

Nat Med. 2019 Feb;25(2):277-283. doi: 10.1038/s41591-018-0304-3. Epub 2019 Jan 21.

PMID:
30664784
16.

Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients.

Picard V, Guitton C, Thuret I, Rose C, Bendelac L, Ghazal K, Aguilar-Martinez P, Badens C, Barro C, Bénéteau C, Berger C, Cathébras P, Deconinck E, Delaunay J, Durand JM, Firah N, Galactéros F, Godeau B, Jaïs X, de Jaureguiberry JP, Le Stradic C, Lifermann F, Maffre R, Morin G, Perrin J, Proulle V, Ruivard M, Toutain F, Lahary A, Garçon L.

Haematologica. 2019 Aug;104(8):1554-1564. doi: 10.3324/haematol.2018.205328. Epub 2019 Jan 17.

17.

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.

Högel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J, Airas L.

Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380. [Epub ahead of print]

PMID:
30570436
18.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

19.

Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury.

Depoorter A, Neumann RP, Barro C, Fisch U, Weber P, Kuhle J, Wellmann S.

Front Neurol. 2018 Nov 20;9:984. doi: 10.3389/fneur.2018.00984. eCollection 2018.

20.

NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Hayer SN, Krey I, Barro C, Rössler F, Körtvelyessy P, Lemke JR, Kuhle J, Schöls L.

Neurology. 2018 Oct 16;91(16):755-757. doi: 10.1212/WNL.0000000000006357. Epub 2018 Sep 14. No abstract available.

PMID:
30217938
21.

Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke.

Tiedt S, Duering M, Barro C, Kaya AG, Boeck J, Bode FJ, Klein M, Dorn F, Gesierich B, Kellert L, Ertl-Wagner B, Goertler MW, Petzold GC, Kuhle J, Wollenweber FA, Peters N, Dichgans M.

Neurology. 2018 Oct 2;91(14):e1338-e1347. doi: 10.1212/WNL.0000000000006282. Epub 2018 Sep 14.

PMID:
30217937
22.

Neurofilaments as biomarkers in neurological disorders.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J.

Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z. Review.

PMID:
30171200
23.

Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden.

Duering M, Konieczny MJ, Tiedt S, Baykara E, Tuladhar AM, Leijsen EV, Lyrer P, Engelter ST, Gesierich B, Achmüller M, Barro C, Adam R, Ewers M, Dichgans M, Kuhle J, de Leeuw FE, Peters N.

J Stroke. 2018 May;20(2):228-238. doi: 10.5853/jos.2017.02565. Epub 2018 May 31.

24.

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J.

Brain. 2018 Aug 1;141(8):2382-2391. doi: 10.1093/brain/awy154.

PMID:
29860296
25.

Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors.

Pinter D, Gattringer T, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, Pichler A, Barro C, Eppinger S, Pirpamer L, Bachmaier G, Ropele S, Wardlaw JM, Kuhle J, Khalil M, Fazekas F.

J Cereb Blood Flow Metab. 2019 Sep;39(9):1669-1677. doi: 10.1177/0271678X18775215. Epub 2018 May 8.

PMID:
29737904
26.

Neurofilament as Neuronal Injury Blood Marker in Preeclampsia.

Evers KS, Atkinson A, Barro C, Fisch U, Pfister M, Huhn EA, Lapaire O, Kuhle J, Wellmann S.

Hypertension. 2018 Jun;71(6):1178-1184. doi: 10.1161/HYPERTENSIONAHA.117.10314. Epub 2018 Apr 23.

PMID:
29686016
27.

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, Kappos L, Zipp F, Bittner S.

Mult Scler. 2019 Apr;25(5):678-686. doi: 10.1177/1352458518765666. Epub 2018 Mar 15.

PMID:
29542376
28.

Serum neurofilament light chain in patients with acute cerebrovascular events.

De Marchis GM, Katan M, Barro C, Fladt J, Traenka C, Seiffge DJ, Hert L, Gensicke H, Disanto G, Sutter R, Peters N, Sarikaya H, Goeggel-Simonetti B, El-Koussy M, Engelter S, Lyrer PA, Christ-Crain M, Arnold M, Kuhle J, Bonati LH.

Eur J Neurol. 2018 Mar;25(3):562-568. doi: 10.1111/ene.13554. Epub 2018 Jan 24.

29.

Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.

Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, Gray E, Grosskreutz J, Jardel C, Kuhle J, Koerner S, Lamari F, Amador MDM, Mayer B, Morelli C, Muckova P, Petri S, Poesen K, Raaphorst J, Salachas F, Silani V, Stubendorff B, Turner MR, Verbeek MM, Weishaupt JH, Weydt P, Ludolph AC, Otto M.

Neurology. 2018 Jan 2;90(1):e22-e30. doi: 10.1212/WNL.0000000000004761. Epub 2017 Dec 6.

PMID:
29212830
30.

Neurofilament light chain predicts disease activity in relapsing-remitting MS.

Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, Wergeland S, Bindoff LA, Kuhle J, Vedeler C.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.

31.

Serum neurofilament light is sensitive to active cerebral small vessel disease.

Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, Pichler A, Barro C, Gröbke S, Voortman M, Pirpamer L, Hofer E, Ropele S, Schmidt R, Kuhle J, Fazekas F, Khalil M.

Neurology. 2017 Nov 14;89(20):2108-2114. doi: 10.1212/WNL.0000000000004645. Epub 2017 Oct 18.

32.

Fluid biomarker and electrophysiological outcome measures for progressive MS trials.

Barro C, Leocani L, Leppert D, Comi G, Kappos L, Kuhle J.

Mult Scler. 2017 Oct;23(12):1600-1613. doi: 10.1177/1352458517732844. Review.

PMID:
29041870
33.

Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy.

Bischof A, Manigold T, Barro C, Heijnen I, Berger CT, Derfuss T, Kuhle J, Daikeler T.

Ann Rheum Dis. 2018 Jul;77(7):1093-1094. doi: 10.1136/annrheumdis-2017-212045. Epub 2017 Jul 25. No abstract available.

PMID:
28743789
34.

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group.

Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954.

35.

Serum neurofilament is associated with progression of brain atrophy and disability in early MS.

Kuhle J, Nourbakhsh B, Grant D, Morant S, Barro C, Yaldizli Ö, Pelletier D, Giovannoni G, Waubant E, Gnanapavan S.

Neurology. 2017 Feb 28;88(9):826-831. doi: 10.1212/WNL.0000000000003653. Epub 2017 Feb 1.

36.

Neurofilament light chain: a biomarker for genetic frontotemporal dementia.

Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA, Borroni B, Galimberti D, Laforce RJ, Masellis M, Vandenberghe R, Ber IL, Otto M, van Minkelen R, Papma JM, Rombouts SA, Balasa M, Öijerstedt L, Jelic V, Dick KM, Cash DM, Harding SR, Jorge Cardoso M, Ourselin S, Rossor MN, Padovani A, Scarpini E, Fenoglio C, Tartaglia MC, Lamari F, Barro C, Kuhle J, Rohrer JD, Teunissen CE, van Swieten JC.

Ann Clin Transl Neurol. 2016 Jul 1;3(8):623-36. doi: 10.1002/acn3.325. eCollection 2016 Aug.

37.

Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum.

Wilke C, Preische O, Deuschle C, Roeben B, Apel A, Barro C, Maia L, Maetzler W, Kuhle J, Synofzik M.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1270-1272. doi: 10.1136/jnnp-2015-312972. Epub 2016 May 17. No abstract available.

PMID:
27188986
38.

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å, Liman V, Norgren N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61. doi: 10.1515/cclm-2015-1195.

PMID:
27071153
39.

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.

Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, Yaldizli Ö, Regeniter A, Derfuss T, Canales M, Schluep M, Du Pasquier R, Krueger G, Granziera C.

Mult Scler. 2016 Oct;22(12):1550-1559. Epub 2016 Jan 11.

PMID:
26754800
40.

[Management of thrombotic thrombocytopenic purpura in two French centers: A series of 27 patients].

Deroux A, Sirodot M, Daguindau N, Barro C, Coppo P, Bouillet L.

Rev Med Interne. 2016 Jan;37(1):13-8. doi: 10.1016/j.revmed.2015.05.003. Epub 2015 Jun 9. French.

PMID:
26065327
41.

Neurofilament Light Chain Determination from Peripheral Blood Samples.

Limberg M, Disanto G, Barro C, Kuhle J.

Methods Mol Biol. 2016;1304:93-8. doi: 10.1007/7651_2015_206.

PMID:
25687302
42.

Long-term therapy with bevacizumab in a patient with Glanzmann's thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions.

Marlu R, Barthelon J, Durand A, Mathieu N, Barro C, Granger V, Tatu A, Pernod G, Polack B, Bonaz B.

Am J Gastroenterol. 2015 Feb;110(2):352-3. doi: 10.1038/ajg.2014.391. No abstract available.

PMID:
25646919
43.

HBB loss of heterozygosity in the hemopoietic lineage gives rise to an unusual sickle-cell trait phenotype.

Joly P, Schluth-Bolard C, Lacan P, Barro C, Pissard S, Labalme A, Sanlaville D, Badens C.

Haematologica. 2013 Jan;98(1):e7-8. doi: 10.3324/haematol.2012.071167. Epub 2012 Oct 12. No abstract available.

44.

A new Frameshift mutation on the α2-globin gene causing α⁺-thalassemia: codon 43 (TTC>-TC or TTC>T-C).

Joly P, Lacan P, Garcia C, Barro C, Francina A.

Hemoglobin. 2012;36(5):508-10.

PMID:
22738776
45.

[Risk groups in differentiated thyroid carcinomas].

Herránz González-Botas J, Barro CV, Vidal JM.

Acta Otorrinolaringol Esp. 2011 Jan-Feb;62(1):14-9. doi: 10.1016/j.otorri.2010.09.007. Epub 2010 Nov 26. Spanish.

46.

Two new G gamma chain variants: Hb F-Saint-Etienne [G gamma 79(EF3)Asp-->His] and Hb F-Lyon [G gamma 97(FG4)His-->Arg].

Joly P, Lacan P, Garcia C, Berger C, Perier C, Barro C, Francina A.

Hemoglobin. 2008;32(5):491-7. doi: 10.1080/03630260802341653.

PMID:
18932075
47.

Should plasma homocysteine be used as a biomarker of venous thromboembolism? A case-control study.

Ducros V, Barro C, Yver J, Pernod G, Polack B, Carpentier P, Desruet MD, Bosson JL.

Clin Appl Thromb Hemost. 2009 Oct;15(5):517-22. doi: 10.1177/1076029608322548. Epub 2008 Sep 25.

PMID:
18818229
48.

Discordant D-dimer results of two rapid quantitative automated assays are related to age.

Barro C, Bosson JL, Satger B, Polack B, Pernod G.

J Thromb Haemost. 2008 Nov;6(11):1970-1. doi: 10.1111/j.1538-7836.2008.03149.x. Epub 2008 Aug 30. No abstract available.

49.

Two new alpha-thalassemia point mutations that are undetectable by biochemical techniques.

Joly P, Pégourie B, Courby S, Barro C, Besson G, Cohen L, Garcia C, Francina A.

Hemoglobin. 2008;32(4):411-7. doi: 10.1080/03630260802173791.

PMID:
18654892
50.

The paradoxical association between inherited factor VII deficiency and venous thrombosis.

Marty S, Barro C, Chatelain B, Fimbel B, Tribout B, Reynaud J, Schved JF, Giansily-Blaizot M.

Haemophilia. 2008 May;14(3):564-70. doi: 10.1111/j.1365-2516.2007.01647.x. Epub 2008 Feb 13.

PMID:
18282149

Supplemental Content

Support Center